Cencora reported $332.8B of revenue over the trailing twelve months, +5.1% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $332.8B (to Q3 2026). Net income: $2.62B, trailing twelve months to Q3 2026. Free cash flow: $4.06B, trailing twelve months to Q3 2026. Operating margin: 0.92%, trailing twelve months to Q3 2026.

CORCencora

Healthcare

$323.83+12% 1Y

$323.83

$252.1652 weeks$373.25

COR as reported

Cencora reported $332.8B of revenue over the trailing twelve months, +5.1% on the year before. 11 reported series are charted on this page, each one as filed.

$332.8B

Revenue, trailing twelve months · to Q3 2026 · +5.1% against the twelve months before

Net income: $2.62B
Net income · +38% year on year · trailing twelve months to Q3 2026
Free cash flow: $4.06B
Free cash flow · +256% year on year · trailing twelve months to Q3 2026
Operating margin: 0.92%
Operating margin · trailing twelve months to Q3 2026

Details›

Every series Ryufin has for COR, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$332.8B	+5.1%	Q3 2026
Net income	$2.62B	+38%	Q3 2026
EPS	$13.47	+38%	Q3 2026
Gross margin	4.0%	n/a	Q3 2026
Operating margin	0.92%	n/a	Q3 2026
Net margin	0.81%	n/a	Q3 2026
ROE	87%	n/a	Q3 2026
ROA	2.6%	n/a	Q3 2026
ROIC	26%	n/a	Q3 2026
Free cash flow	$4.06B	+256%	Q3 2026
P/E	24.0	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.